Our technological innovation platform called “CleanWeb-MAP” (CleanWeb Managed Access Programme) facilitates access to new drugs by eligible patients.
There are multiple terms that fall under the umbrella of MAP, including Compassionate Use, Early Access, Named Patient Use and Individual Patient Request Programmes to name but a few. The terms used may vary from country to country depending on local laws and regulations. Our module is closely linked to our CleanWeb software platform for medical data collection, it enables self-registration of prescribing physicians and pharmacists, for each new product related to MAP.
• MAPs provide alternative treatments to patients with life-threatening diseases with no therapeutic options
• CleanWeb-MAP meets local laws and regulations Seamless Managed Access Programmes
Allows you to gain valuable early experience with a product
CleanWeb-MAP facilitates the management of MAPs in real-life conditions
Each role and access are clearly defined Physicians, Nurses, Medical Advisor, Programme Manager, Pharmacovigilance officer, Logistics perfectly interact in the MAP cycle process.
The ordering process and the availability of drugs are assured in interaction with any external system and data source.
CleanWeb-MAP allows for the involvement of other stakeholders and for the integration of many additional behaviours (e.g., Pharmacist).
Do you want to learn more about our e-health solution? Just fill in the form and we will get back to you shortly
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
20 000 +
2 million +
50 000 +
May 22, 2023
Wednesday may 24 TELEMEDICINE TECHNOLOGIES will be present at SantExpo on the OVHcloud stand as a partner of the “Open Trusted Cloud” program. Our president Yoani Matsakis will be representing Telemedicine Technologies, and wil intervene next to Mathieu Godart, CTO and co-founder of SÊMEIA and Emmanuel MEYRIEUX, Client Security manager at OVHcloud. Throughout the day you […]
May 22, 2023
Fierce Biotech The FDA seems to be satisfied that Pfizer’s RSV vaccine is safe and effective for administration in pregnant women to protect infants from severe disease. The agency’s confidence was revealed in briefing documents filed ahead of an advisory committee meeting set for Thursday. The Vaccines and Related Biological Products Advisory Committee will consider […]
May 22, 2023
Trial Site News The World Health Organisation (WHO) decided Thursday May 4, 2023, to end the COVID-19 public health emergency of international concern (PHEIC). TrialSite cautions that this is a provisional (temporary) status while WHO considers its forward-looking options (2023-2025). Importantly, in “The COVID-19 Emergency is Over, Sort of,” TrialSite reports that in America some […]